Please read this leaflet carefully before you start using TRELEGY ELLIPTA. This leaflet answers some common questions about TRELEGY ELLIPTA. It does not contain all the available information.

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

The biotech industry offers a compelling investment opportunity due to its potential for disruptive innovations and high ...

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, ...

But while topline results, published in May, suggest its new drug Relvar Ellipta is a step forward in treatment, the full trial data paints a more down-to-earth reality – with some disappointing ...

After hours: October 18 at 4:02 PM EDT Loading Chart for INVA ...

CMS is expected to announce in early 2025 the list of up to 15 Medicare Part D drugs that will be subject to price negotiations in 2025, with negotiated prices expected to be implemented in 2027.

Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.

Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through your mouth so they can directly reach your lungs. If your healthcare ...

With prices finalized for the first 10 Medicare Part D drugs selected for the initial round of pricing negotiations, attention now turns to the next 15 drugs the U.S. government is eyeing for the ...